Published 13 days ago • loading... • Updated 10 days ago

FDA Expands Guselkumab Approval to Crohn's Disease

Summary by MedPage Today

(MedPage Today) -- The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 inhibitor that also binds...

12 Articles

All

Left

Center

Right

Science Daily

Center

Cellular mechanisms that may lead to onset of inflammatory bowel disease

New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease.

11 days ago·United States

Read Full Article

MedPage Today

Center

FDA Expands Guselkumab Approval to Crohn's Disease

13 days ago·New York, United States

Read Full Article

Morning Sun

Finding Clinical Trial Resources - The Morning Sun

(Family Features) If you have Crohn’s disease or ulcerative colitis, a clinical trial may be an option for you. Clinical trials are necessary for finding new ways of preventing, detecting or treating these diseases and others. To learn more about inflammatory bowel disease clinical research, visit crohnscolitisfoundation.org/clinical-trials-community and consider resources from the Crohn’s & Colitis Foundation that can provide information on typ…

10 days ago·Pittsburg, United States

Read Full Article

THIP Media

Researchers find mechanisms that may lead to inflammatory bowel...

Last Updated on March 23, 2025 by Team THIP New York, March 23 (IANS) A team of scientists has discovered mechanisms of abnormal immune cell function that may lead to Crohn’s disease, an inflammatory bowel disease (IBD). Crohn’s disease causes chronic inflammation of the gastrointestinal (GI) tract, and symptoms can include abdominal pain, diarrhoea, weight […] The post Researchers find mechanisms that may lead to inflammatory bowel disease appe…

11 days ago

Read Full Article

centerforbiosimilars.com

Patients With IBD Maintain Therapy 2 Years Post-Switching to Infliximab Biosimilar

People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.

11 days ago

Read Full Article

MyChesCo

FDA Approves TREMFYA® for Crohn's Disease, Offering New Treatment Options

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD). This approval marks a significant milestone as TREMFYA becomes the first and only interleukin-23 (IL-23) inhibitor available with both subcutaneous (SC) and intravenous (IV) induction options. The approval of TREMFYA is su…

12 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year